Merrill stays neutral on Acambis

Acambis plc was kept at a neutral rating by Merrill Lynch analyst Peter Welford on news that Intercell has received European orphan drug status for its Japanese encephalitis vaccine IC51, the most significant competitor for Acambis' ChimeriVax-JE. This could potentially exclude Acambis from the European market for 10 years. Merrill's forecasts for Acambis' ChimeriVax-JE already assumed minimal sales in Europe. Shares of the Cambridge, England, biotechnology company were down 5 cents, or 0.71%, at $6.95 on volume of 9,766 shares versus the three-month running average of 31,096 shares. (Nasdaq: ACM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.